Drugs / Poseltinib
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT03099148 | Apr → May 2017 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03083561 | Mar → May 2017 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT02914379 | Sep → Nov 2016 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01765478 | Jan 2013 → Nov 2014 | rheumatoid arthritis | Hanmi Pharmaceutical Company Limited | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07269639 | Jan 2026 → Dec 2027 expected | large B-cell lymphoma | Seoul National University Hospital | Not yet recruiting | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT06737250 | Nov 2024 → Jun 2026 overdue | primary central nervous system lymphoma | NOBO Medicine | Recruiting | No outcome recorded |
| Phase 2 | NCT05335018 | May 2022 → Nov 2025 overdue | diffuse large B-cell lymphoma | Seoul National University Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02628028 | Aug 2016 → Apr 2018 | rheumatoid arthritis | Eli Lilly and Company | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2023-06-22 | Hanmi Pharmaceutical Company Limited | Results Hanmi Pharmaceutical confirms new indication for returned new drug, exploring the possibility of a turn around hanmipharm.com ↗
This study, supported by Hanmi Pharmaceutical and Genome Opinion, confirmed the triple-drug combination therapy's safety and effectiveness, including poseltinib in relapsed and refractory diffuse large B-Cell lymphoma (DLBCL). |
| 2023-06-12 | Hanmi Pharmaceutical Company Limited | Results 한미약품 또 반전, 반환된 신약에서 새 적응증 확인 hanmi.co.kr ↗
임상 시작 후 반응이 평가된 환자 14명 중 유효성 평가 기준인 객관적 반응(OR)을 충족한 비율이 79%에 이르고, 초기 데이터임에도 불구하고 36% 환자는 암 세포가 사라진 완전관해(CR)가 관찰됐다. |
| 2018-02-14 | Hanmi Pharmaceutical Company Limited | Results <공지 및 설명자료> 릴리 임상 변동 및 이에 대한 한미약품 설명자료 hanmi.co.kr ↗
릴리(Lilly)가 진행하던 BTK억제제(LY3337641/HM71224)의 류마티스관절염 환자 대상 임상 2상이 중단되고, 양사가 다른 적응증 개발을 협의 중이다. |
| 2014-06-17 | Hanmi Pharmaceutical Company Limited | Results Hanmi pharmaceutical novel rheumatoid arthritis drug, EULAR poster presentation hanmipharm.com ↗
According to the presentation, a proportional absorption of HM71224 in body to increasing dose was observed in healthy volunteers from both single dose and multiple doses. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-06-22 | Hanmi Pharmaceutical Company Limited | Hanmi Pharmaceutical confirms new indication for returned new drug, exploring the possibility of a turn around hanmipharm.com ↗ |
| 2023-06-12 | Hanmi Pharmaceutical Company Limited | 한미약품 또 반전, 반환된 신약에서 새 적응증 확인 hanmi.co.kr ↗ |
| 2018-02-14 | Hanmi Pharmaceutical Company Limited | <공지 및 설명자료> 릴리 임상 변동 및 이에 대한 한미약품 설명자료 hanmi.co.kr ↗ |
| 2017-03-08 | Hanmi Pharmaceutical Company Limited | <보도자료> 한미약품 개발 신약 HM71224, WHO 국제일반명 등재 hanmi.co.kr ↗ |
| 2014-06-17 | Hanmi Pharmaceutical Company Limited | Hanmi pharmaceutical novel rheumatoid arthritis drug, EULAR poster presentation hanmipharm.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Poseltinib | “OBJECTIVE: To evaluate the efficacy and safety of poseltinib (formerly LY3337641/HM71224), an irreversible covalent inhibitor of Bruton's tyrosine kinase in a 2-part, phase II...” PMID 33323529 ↗ Dec 20203“NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL” NCT06737250 ↗ |
| Known as | HM71224 | “OBJECTIVE: To evaluate the efficacy and safety of poseltinib (formerly LY3337641/HM71224), an irreversible covalent inhibitor of Bruton's tyrosine kinase in a 2-part, phase II...” PMID 33323529 ↗ Dec 2020 |
| Known as | LY3337641 | “OBJECTIVE: To evaluate the efficacy and safety of poseltinib (formerly LY3337641/HM71224), an irreversible covalent inhibitor of Bruton's tyrosine kinase in a 2-part, phase II...” PMID 33323529 ↗ Dec 2020 |
| Known as | NB02 | “NB02 (Poseltinib) Combined Rituximab and Lenalidomide in R/R PCNSL” NCT06737250 ↗ |
| Action | Inhibit | “HM71224 is a potent small molecule inhibitor of Bruton's tyrosine kinase (BTK).” NCT01765478 ↗ |
| Modality | Small molecule | “HM71224 is a potent small molecule inhibitor of Bruton's tyrosine kinase (BTK).” NCT01765478 ↗ |
| Route | Oral | “single and multiple oral dose administration of HM71224” NCT01765478 ↗ |
| Target | BTK | “HM71224 is a potent small molecule inhibitor of Bruton's tyrosine kinase (BTK).” NCT01765478 ↗ |